A first-of-its-kind clinical study may offer new hope to patients battling rectal cancer.
The Phase 2 study, newly underway at Providence Cancer...
With the release of her book Patient 71, Australia native Julie Randall has given cancer patients across the globe hope for life after cancer. Her remarkable story of overcoming stage IV metastatic melanoma was featured in a segment by 60 Minutes Australia chronicling her shocking diagnosis, promise to her family and determination to become “Patient 71” in an immunotherapy clinical trial at Providence Cancer Center.
Known as "Patient 71," persistence paid off for Australian cancer patient Julie Randall
Learn more about her story ›
She now devotes her...
The Earle A. Chiles Research Institute, a division of Providence Cancer Center in Portland, Ore., was well-represented at the 2017 annual meeting of the American Society of Clinical Oncology held June 2-6 in Chicago, Ill.
It has been a busy and exciting start to 2017 for immunotherapy researcher Eric Tran, Ph.D., and it could make a great difference in the lives of people fighting cancer.
More than 20 studies of promising new therapies for lung cancer patients are open now at Providence Cancer Center, including studies of targeted therapies and novel immunotherapy combinations.
First-in-human data presented at GTCBio 9th Immunotherapeutics & Immunomonitoring Conference
Immunotherapy is a treatment approach that harnesses the immune system to recognize, attack and eliminate cancer.
The opportunity to conduct...
Patients with a variety of cancer types are eligible to receive new and promising treatments when they participate in Phase I research studies at Providence Cancer Center.
Providence physicians and scientists have been leading the way in melanoma research and treatment for more than 20 years. Our findings have resulted in new ways to boost immune response, which has improved the standard of care for patients with this aggressive malignancy.